Clinical TrialsThe initiation of ALG-000184's randomized, double-blind, active-controlled Phase 2 study is regarded as Aligos' next major milestone.
Regulatory SupportAligos is moving toward a more attainable goal, and one that is expected to be supported and endorsed by the FDA, EMA, and NMPA.
Therapeutic PotentialALG-000184 showcased robust and sustained antiviral activity in both HBeAg-positive and HBeAg-negative patients with CHB, highlighting its potential as a first-line therapy for long-term viral suppression.